Our goal: eliminate COVID-19. For good.
Our subsidiary ViralClear Pharmaceuticals, Inc. is comprised of an accomplished group of pharmaceutical industry veterans. We are working around the clock towards a safe and efficient solution to the COVID-19 pandemic. ViralClear is currently developing a novel, potent, orally administered, broad-spectrum anti-viral agent, merimepodib.
An Urgent Global Challenge:
At the time of writing (early August 2020), the novel coronavirus has resulted in over 18 million confirmed global cases and 689 thousand global deaths.* As the United States and other countries continue to struggle with public health and economic burdens due to COVID-19, the need for effective treatments is urgent.
The last time the world responded to a global emerging disease epidemic of the scale of COVID-19 was the 1918-1919 H1N1 influenza pandemic, which killed at least 50 million people globally. Even with modern technology and healthcare, experts expect upwards of several million deaths globally as a result of COVID-19.
*Source: World Health Organization, Johns Hopkins University Coronavirus Resource, Centers for Disease Control and Prevention
ViralClear Pharmaceuticals, Inc. is developing a novel anti-viral agent to treat COVID-19 using the chemical compound, merimepodib.
Merimepodib has already undergone extensive testing and human clinical experience (with more than 300 treated patients for other indications) as part of a development process for treating viral infections. We expect that this broad-spectrum pharmaceutical could be used alone or in combination with other anti-viral agents or immune modulators.
Merimepodib has demonstrated strong activity against COVID-19 in cell cultures in in-vitro laboratory testing. The product is intended to be orally administered (either as softgel capsules or liquid formulations). The small molecule nature of the pharmaceutical allows for it to be scaled rapidly to meet dire needs in times of global pandemics.
On May 13th, 2020, ViralClear’s Executive Chair and Acting Chief Medical Officer, Jerome B. Zeldis, co-authored and contributed to an F1000 Research article on merimepodib. The study focused on testing merimepodib in combination with remdesivir, a pharmaceutical by Gilead, which is currently authorized for emergency use in the United States.
This research provides evidence that, when administered in combination, merimepodib and remdesivir might be an effective treatment for COVID-19 cases. Researchers found that merimepodib reduces the infectious titer of SARS-CoV-2 more effectively than remdesivir at the same concentration. When used in combination, researchers found the infectious titer of SARS-CoV-2 to be reduced to undetectable levels.
On June 17th, ViralClear announced the commencement of patient enrollment in its Phase II trial for merimepodib. The study is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of merimepodib as an orally administered treatment. The trial is designed for hospitalized patients who have confirmed infection with SARS-CoV-2 and require supplemental oxygen.
This is the most significant healthcare crisis in a generation. With passion and urgency, ViralClear Pharmaceuticals, Inc. is committed to doing everything it can to help.
Media inquiries: email@example.com